Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $4.63 (54.17% upside)

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetActions
5/19/2015Leerink SwannLower Price TargetOutperform$23.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/1/2015ZacksUpgradeSell -> Hold$3.25View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Leerink SwannInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Cowen and CompanyInitiated CoverageOutperform$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2014Citigroup Inc.Initiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 5/25/2013 forward)